<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003640</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30971</org_study_id>
    <secondary_id>EORTC-30971</secondary_id>
    <nct_id>NCT00003640</nct_id>
  </id_info>
  <brief_title>Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer</brief_title>
  <official_title>A Feasibility Study of Thorough Transurethral Resection (TURB) and Escalated Dose M-VAC Chemotherapy as Primary Treatment of T2-T3a, N0-Nx, M0 Transitional Cell Carcinoma of the Bladder, With the Intention of Bladder Preservation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combination chemotherapy combined with transurethral resection may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of transurethral resection plus&#xD;
      combination chemotherapy in treating patients who have stage II or stage III bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the percentage of patients with transitional cell carcinoma of the&#xD;
      bladder who are disease free or who have minimal disease 3 months after thorough&#xD;
      transurethral resection (TURB) and escalated dose&#xD;
      methotrexate/vinblastine/doxorubicin/cisplatin (M-VAC) chemotherapy. II. Evaluate the&#xD;
      combination of thorough TURB and escalated dose M-VAC followed by radiotherapy with respect&#xD;
      to bladder preservation for patients who respond to neoadjuvant chemotherapy. III. Evaluate&#xD;
      the proportion of patients remaining disease free and not requiring cystectomy at 1 year. IV.&#xD;
      Evaluate the feasibility and morbidity of this treatment schedule in multiple institutions&#xD;
      applied by urologists of possibly varying endoscopic ability.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients undergo a local transurethral resection.&#xD;
      Patients then receive methotrexate IV on day 1, followed by vinblastine IV, doxorubicin IV,&#xD;
      and cisplatin IV on day 2. Filgrastim (G-CSF) is administered on days 4-10. Chemotherapy is&#xD;
      repeated every 14 days for 3 courses. After the end of chemotherapy, patients undergo another&#xD;
      local transurethral resection in order to define response to treatment. Patients with minimal&#xD;
      or no disease are treated with radiotherapy. Patients who still have disease undergo a&#xD;
      cystectomy. Patients are followed every 3 months for the first 2 years, and then every 6&#xD;
      months until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 29-73 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">November 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Transitional cell carcinoma of the bladder with biopsy proven&#xD;
        muscle invasion suitable for resection leaving no residual visible or palpable tumor mass&#xD;
        Unifocal No greater than 5 cm Stages II and III (T2-T3a, N0-NX, M0) No prior treatment for&#xD;
        bladder cancer other than endoscopic resection, intravesical chemotherapy, or intravesical&#xD;
        immunotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-1 Life expectancy:&#xD;
        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 120,000/mm3&#xD;
        Hepatic: Bilirubin normal SGOT/SGPT normal Renal: GFR at least 50 mL/min Cardiovascular:&#xD;
        Normal cardiac function (i.e., no New York Heart Association class II-IV) Other: Normal&#xD;
        auditory function No second primary malignant tumor except basal cell carcinoma of the skin&#xD;
        Fit for cisplatin containing combination chemotherapy, radical radiotherapy, or cystectomy&#xD;
        No active infections Not pregnant or nursing No concurrent illness that significantly&#xD;
        affects clinical assessments&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See&#xD;
        Disease Characteristics No prior systemic chemotherapy Endocrine therapy: Not specified&#xD;
        Radiotherapy: No prior radiotherapy to the bladder Surgery: See Disease Characteristics No&#xD;
        prior partial cystectomy Prior transurethral resection of the bladder allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cora N. Sternberg, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Scientifico H. San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2004</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

